Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	21.18B
Revenue (ttm)	16.63B
Net Income (ttm)	-157.00M
Shares Out	1.15B
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	7.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,291,794
Open	18.95
Previous Close	18.80
Day's Range	18.31 - 19.10
52-Week Range	12.47 - 22.80
Beta	0.62
Analysts	Strong Buy
Price Target	24.71 (+33.86%)
Earnings Date	Jul 30, 2025

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 36,830
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Financial Performance

In 2024, Teva Pharmaceutical's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Analyst Summary

According to 7 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $24.71, which is an increase of 33.86% from the latest price.

Price Target

$24.71

(33.86% upside)

Analyst Consensus: Strong Buy